search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


13 resulaten gevonden voor Celgene in trials

A national quality registry for spondyloarthritis in daily practice in the Netherlands
- TRIAL ID
NTR6740
- ACRONYMSpA-Net
NABGEM study: nab-paclitaxel plus gemcitabine in patients with locally unresectable pancreatic cancer.
- TRIAL ID
NTR6645
- ACRONYMNABGEM study
Real world data collection and population-based analysis of incidence of patients with acute myeloid leukemia (AML).
- TRIAL ID
NTR6105
- ACRONYM
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients.
- TRIAL ID
NTR5350
- ACRONYMHOVON 129 PCL
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib.
- TRIAL ID
NTR5349
- ACRONYMHOVON 114 MM
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U.
- TRIAL ID
NTR5267
- ACRONYMHOVON 130 NHL
Prospective study of quantitative molecular minimal residual disease (MRD) monitoring in pediatric acute myeloid leukemia (AML).
- TRIAL ID
NTR3482
- ACRONYMQMRD in AML
Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): A phase II trial.
- TRIAL ID
NTR3052
- ACRONYMHOVON 109 CLL
ReBeL study: A randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma. A HOVON/GLSG study.
- TRIAL ID
NTR3028
- ACRONYMHOVON 110 FL / GLSG
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
- TRIAL ID
NTR2294
- ACRONYMHOVON 103 AML Lenalidomide
A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.
- TRIAL ID
NTR1825
- ACRONYMHOVON 89 MDS
Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (>= 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t).
- TRIAL ID
NTR1810
- ACRONYMHOVON 97 AML
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma.
- TRIAL ID
NTR1440
- ACRONYMHOVON 86 MM